Our Treatments
Our Treatments
EPM is committed to developing a series of new therapeutic solutions based on cannabinoid acids which provide alternative treatments for patients. This is the driving force behind EPM’s research program. Although cannabinoid acids are potential treatments for a wide range of diseases, currently, EPM focuses on three main therapeutic conditions based on its lead molecule EPM301: Inflammatory Bowel Disease, inflammatory skin disease (psoriasis) and Acute Respiratory Distress Syndrome in COVID-19 patients.
Selected formulation
Oral
Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated in 2023.
EPM's potential solution
The treatment is based on EPM301 and has been evaluated in both acute (DSS induced mouse colitis) and chronic (IL-10 knock-out mouse) animal models of IBD and has shown similar activity to prednisone (acute model) and anti-TNFa mAb (chronic model) when administered by gavage.
Selected formulation
Topical
Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated in Q4/2022.
EPM's potential solution
The treatment is based on EPM301 and has been evaluated in an ex vivo model of inflammatory skin disease. When applied topically, it displayed similar activity to hydrocortisone
Selected formulation
IV
Expected clinical trail timeline
IND approval to treat COVID-19 patients with poor prognosis under compassionate usage grounds is yet to be defined.
EPM's potential solution
The treatment is based on EPM301 and has demonstrated anti-inflammatory activity in a number of models of inflammatory disease (acute and chronic colitis, inflammatory skin diseases) when administered both orally and topically. EPM301 was also well tolerated in a 7-day IV toxicity study in rats.
